(Q39524841)

12 September 2017

Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up (English)

1 reference

12 September 2017

Letterie GS

1

1 reference

12 September 2017

Coddington CC

2

1 reference

12 September 2017

Winkel CA

3

1 reference

12 September 2017

Shawker TH

4

1 reference

12 September 2017

Loriaux DL

5

1 reference

12 September 2017

Collins RL

6

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 June 1989

1 reference

12 September 2017

Fertility and Sterility

1 reference

12 September 2017

51

1 reference

12 September 2017

6

1 reference

12 September 2017

951-956

1 reference

Uterine leiomyomata: etiology, symptomatology, and management.

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Induction of degenerative changes in uterine myomas by high-dosage progestin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Leiomyomas: steroid receptor content. Variation within normal menstrual cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Effects of the (imBzl)D-His6, Des-Gly analog of GnRH on gonadotropin and estradiol secretion in normal women

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

The inaccuracy of total uterine volume measurements: sources of error and a proposed solution.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960724-0

7 January 2021

10.1016/S0015-0282(16)60724-0

Identifiers

DOI

0 references

1 reference